Breaking Down Toxicity Considerations for Non-Cytotoxic Payloads & Alternative Antibody Formats to Unlock Differentiated ADC Therapeutic Index
- Understanding the need for ADC novelty to overcome patient resistance and deliver differentiated tolerability to widen therapeutic index
- Evaluating the tolerability of ISACs and AOCs to assess the risk benefit profiles of alternate payload mechanisms
- Understanding how considerations across bystander activity and target selection are crucial to manager toxicity of bispecific and peptide drug conjugates